Parathyroid hormone added to established hormone therapy: Effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal

Journal of Bone and Mineral Research

Volumn 16, Issue 5, 2001, Pages 925-931

  Cosman, F ^a,b   Nieves, J ^a,b   Woelfert, L ^a   Formica, C ^a   Gordon, S ^a   Shen, V ^a   Lindsay, R ^a,b  

^a HELEN HAYES HOSPITAL   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Bone mass increase; Hormone replacement; Osteoporosis; Parathyroid hormone; Vertebral fracture

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; PARATHYROID HORMONE; VITAMIN D;

ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; BONE RADIOGRAPHY; BONE TURNOVER; CLINICAL TRIAL; FEMALE; HEMOSTASIS; HIP; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; SPINE; VERTEBRA FRACTURE;

EID: 0035063315     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2001.16.5.925     Document Type: Article

References (29)

1. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
2. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
3. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
4. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial
5. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
6. Effect of risedronate and the risk of hip fracture in elderly women
7. Studies of calcium phosphorus metabolisms: Study of bone trabeculae as ready available reserve supply of calcium
8. On the stimulation of new bone-formation with parathyroid extract and irradiated ergosterol
9. Is parathyroid hormone a therapeutic option for osteoporosis? A review of the clinical evidence
10. Randomized controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis
11. Prevention of estrogen deficiency - Related bone loss with human parathyroid hormone-(1-34)
12. A randomized controlled multi-center study of 1-84hPTH for treatment of postmenopausal osteoporosis
13. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical
14. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers
15. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential catcitonin to improve bone mass in postmenopausal women with osteoporosis
16. Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: A randomized double-masked prospective study using three dose levels
17. Amino terminal radioimmunoassays for human PTH
18. The association of radiographically detected vertebral fractures with back pain and function: A prospective study
19. Vertebral fractures and mortality in older women
20. A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fracture
21. Recombinant human PTH [rhPTH(1-34)] reduces the risk of spine and non-spine fractures in postmenopausal osteoperosis
22. Parathyroid hormone 1-34(hPTH 1-34) and estrogen produce dramatic bone density increases in postmenopausal osteoporosis - Results from a placebo-controlled randomized trial
23. Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis
24. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial
25. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women
26. Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: Evidence for de novo bone formation on quiscent cancellous surface
27. Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats
28. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone line cells
29. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone